| scholarly article | Q13442814 |
| P50 | author | Jean-Jacques Wyndaele | Q87725004 |
| P2093 | author name string | Mark Slack | |
| Paul Abrams | |||
| Rainer Lange | |||
| Philip van Kerrebroeck | |||
| Ilker Yalcin | |||
| Richard C Bump | |||
| Duloxetine Urinary Incontinence Study Group | |||
| P2860 | cites work | Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors | Q34105682 |
| Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. | Q35873512 | ||
| α2-Adrenoceptors not imidazole receptors mediate depression of a sacral spinal reflex in the cat | Q43745294 | ||
| Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats | Q44054332 | ||
| Duloxetine versus placebo in the treatment of stress urinary incontinence | Q44062087 | ||
| Validation of two global impression questionnaires for incontinence | Q44513363 | ||
| Pelvic organ prolapse surgery in the United States, 1997. | Q46356979 | ||
| Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats | Q48430391 | ||
| Unmasking of a neonatal somatovesical reflex in adult cats by the serotonin autoreceptor agonist 5-methoxy-N,N-dimethyltryptamine | Q48956020 | ||
| The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 | ||
| Quality of life of persons with urinary incontinence: development of a new measure. | Q53633525 | ||
| P433 | issue | 3 | |
| P921 | main subject | placebo | Q269829 |
| P304 | page(s) | 249-257 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | BJOG: an International Journal of Obstetrics and Gynaecology | Q15724571 |
| P1476 | title | Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence | |
| P478 | volume | 111 |
| Q46801499 | 75NC007 device for noninvasive stress urinary incontinence management in women: a randomized controlled trial |
| Q57463184 | A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence |
| Q80246733 | An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies |
| Q36921864 | An overview of stress urinary incontinence treatment in women |
| Q40656507 | Assessment of overactive bladder in women antidepressant users. |
| Q26860846 | Coadministration of low-dose serotonin/noradrenaline reuptake inhibitor (SNRI) duloxetine with α 2-adrenoceptor blockers to treat both female and male mild-to-moderate stress urinary incontinence (SUI) |
| Q33530261 | Conservative treatment of female stress urinary incontinence |
| Q34552333 | Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports |
| Q35771615 | Current management of stress urinary incontinence |
| Q46051446 | Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study |
| Q36669199 | Dilemmas in the management of female stress incontinence: the role of pelvic floor muscle training |
| Q45902947 | Do predictive parameters exist for therapy with duloxetine in women with stress urinary incontinence? |
| Q80579407 | Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine |
| Q37708622 | Duloxetine Treatment of Stress Urinary Incontinence in Women Does Not Induce Mania or Hypomania |
| Q81359286 | Duloxetine as a treatment for stress incontinence--where are we now? |
| Q30443662 | Duloxetine compared with placebo for treating women with symptoms of overactive bladder |
| Q34770302 | Duloxetine in the treatment of major psychiatric and neuropathic disorders |
| Q24680252 | Duloxetine in the treatment of stress urinary incontinence |
| Q43267071 | Duloxetine in the treatment of stress urinary incontinence |
| Q82277284 | Duloxetine treatment for women awaiting continence surgery |
| Q33316575 | Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial |
| Q35859638 | Duloxetine: a new approach for treating stress urinary incontinence |
| Q44893712 | Duloxetine: an innovative approach for treating stress urinary incontinence |
| Q35933727 | Duloxetine: in stress urinary incontinence |
| Q79424407 | Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence |
| Q33552597 | Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials |
| Q37737694 | Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study. |
| Q89577569 | Evaluation of duloxetine and innovative pelvic floor muscle training in women with stress urinary incontinence (DULOXING): Study protocol clinical trial (SPIRIT Compliant) |
| Q34844161 | Evaluation of efficacy of duloxetine in stress urinary incontinence in women |
| Q81301566 | Impact of duloxetine on quality of life for women with symptoms of urinary incontinence |
| Q80386063 | Incontinence-specific quality of life measures used in trials of treatments for female urinary incontinence: a systematic review |
| Q37587467 | Medical management of stress urinary incontinence: is there a future? |
| Q45194161 | Medical therapy of urinary incontinence |
| Q83914823 | Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence |
| Q34085595 | Neural control of the female urethral and anal rhabdosphincters and pelvic floor muscles |
| Q34020395 | Neural control of the lower urinary tract: peripheral and spinal mechanisms |
| Q46407827 | Nocturia, depression and antidepressant medication |
| Q36729973 | Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice |
| Q46809111 | Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women |
| Q36451416 | Pharmacological management of women with mixed urinary incontinence |
| Q38335674 | Pharmacological treatment of pure stress urinary incontinence: a narrative review |
| Q35826270 | Pharmacotherapy for stress urinary incontinence : present and future options |
| Q46716924 | Polymeric Microspheres for Medical Applications. |
| Q56883294 | Postpartum depression, urge urinary incontinence, and overactive bladder syndrome: is there an association? |
| Q35907276 | Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine |
| Q43096660 | Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies |
| Q42848230 | Properties of urethral rhabdosphincter motoneurons and their regulation by noradrenaline |
| Q45993198 | Reductions in stress urinary incontinence episodes: what is clinically important for women? |
| Q50014986 | Role of the serotonergic system in urethral continence reflexes during sneezing in rats. |
| Q36299961 | Safety and adverse event profile of duloxetine |
| Q46864021 | Sample size estimation for the van Elteren test--a stratified Wilcoxon-Mann-Whitney test |
| Q24246568 | Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults |
| Q34010677 | Stress incontinence. |
| Q36449183 | Stress urinary incontinence in women: diagnosis and medical management. |
| Q46769060 | The effect of duloxetine on urethral sphincter morphology |
| Q79295070 | The effects of duloxetine on urethral function and sphincter morphology |
| Q37360532 | The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. |
| Q34333544 | The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis |
| Q37130272 | The treatment of urinary incontinence with Duloxetine |
| Q46710464 | The use of Duloxetine in the treatment of male stress urinary incontinence |
| Q51582363 | Treatment of stress urinary incontinence using a copolymer system: impact on quality of life. |
| Q80296985 | Treatment of stress urinary incontinence with duloxetine hydrochloride |
| Q37199879 | Update on duloxetine for the management of stress urinary incontinence. |
| Q83283778 | Urethrovaginal fistula--a rare complication after the placement of a suburethral sling (IVS) |
| Q34769139 | Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence |
| Q82203359 | Urinary incontinence in women |
| Q80245310 | What's a 'cure'? Patient-centred outcomes of treatments for stress urinary incontinence |
| Q87311301 | [Pharmacotherapy of urinary incontinence in the elderly] |
Search more.